title: EGFR, HER2÷neu and Ki67 immunoexpression in serous ovarian tumors.
abstract: In this study, we analyzed EGFR, HER2/neu and Ki67 immunoexpression for 26 benign, borderline and malignant serous ovarian tumors. EGFR and HER2/neu immunoreactions were present in some benign/borderline tumors with high/low intensity of immunostain. In poorly differentiated adenocarcinomas, the EGFR/HER2/neu reaction was intense compared to well-differentiated ones. The Ki67 medium proliferation index was 2.1% for benign tumors, 6% in the borderline and 47.7% in malignant tumors. EGFR, HER2/neu and Ki67 can be used to identify benign/borderline tumors with progression potential and the malignant aggressive tumors.
authors.affiliation: Department of Obstetrics and Gynecology, University of Medicine and Pharmacy of Craiova, Craiova, Romania. cristi_marinas84@yahoo.com
authors.forename: M C
authors.initials: MC
authors.lastname: Marinaş
authors.forename: G
authors.initials: G
authors.lastname: Mogoş
authors.forename: Raluca
authors.initials: R
authors.lastname: Ciurea
authors.forename: D G
authors.initials: DG
authors.lastname: Mogoş
mesh_terms: D014408:Biomarkers, Tumor / Q000096:biosynthesis*; D066246:ErbB Receptors / Q000096:biosynthesis*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D019394:Ki-67 Antigen / Q000096:biosynthesis*; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000378:metabolism* / Q000473:pathology; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis*
chemical_list: D014408:Biomarkers, Tumor; D066246:ErbB Receptors; D019394:Ki-67 Antigen; D018719:Erb-b2 Receptor Tyrosine Kinases